ES2042828T3 - Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores. - Google Patents

Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.

Info

Publication number
ES2042828T3
ES2042828T3 ES89103480T ES89103480T ES2042828T3 ES 2042828 T3 ES2042828 T3 ES 2042828T3 ES 89103480 T ES89103480 T ES 89103480T ES 89103480 T ES89103480 T ES 89103480T ES 2042828 T3 ES2042828 T3 ES 2042828T3
Authority
ES
Spain
Prior art keywords
immunotherapy
tumor
preparation procedure
vaccine preparation
virus modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89103480T
Other languages
English (en)
Spanish (es)
Inventor
Volker Prof Dr Schirrmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2042828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2042828T3 publication Critical patent/ES2042828T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES89103480T 1988-03-01 1989-02-27 Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores. Expired - Lifetime ES2042828T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen

Publications (1)

Publication Number Publication Date
ES2042828T3 true ES2042828T3 (es) 1993-12-16

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89103480T Expired - Lifetime ES2042828T3 (es) 1988-03-01 1989-02-27 Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.

Country Status (10)

Country Link
US (1) US5273745A (OSRAM)
EP (1) EP0331102B1 (OSRAM)
JP (1) JPH02504034A (OSRAM)
KR (1) KR900700130A (OSRAM)
AT (1) ATE90877T1 (OSRAM)
AU (1) AU3188989A (OSRAM)
DE (2) DE3806565A1 (OSRAM)
DK (1) DK541889A (OSRAM)
ES (1) ES2042828T3 (OSRAM)
WO (1) WO1989007946A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
JP3580371B2 (ja) * 1991-10-04 2004-10-20 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ サイトカインおよび抗原を用いた全身の免疫応答の調節
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
DE69723580T2 (de) * 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
CA2242590A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
WO2004096244A1 (en) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
ES2380289T3 (es) * 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
WO2014158811A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
JPH02504034A (ja) 1990-11-22
EP0331102B1 (de) 1993-06-23
DE3806565A1 (de) 1989-09-14
AU3188989A (en) 1989-09-22
WO1989007946A1 (fr) 1989-09-08
EP0331102A1 (de) 1989-09-06
US5273745A (en) 1993-12-28
DE58904760D1 (de) 1993-07-29
DK541889D0 (da) 1989-10-31
ATE90877T1 (de) 1993-07-15
DE3806565C2 (OSRAM) 1991-04-25
KR900700130A (ko) 1990-08-11
DK541889A (da) 1989-10-31

Similar Documents

Publication Publication Date Title
ES2042828T3 (es) Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
ES2179105T3 (es) Adyuvantes proteinicos.
DK0538437T3 (da) Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
ES2006925A6 (es) Procedimiento para la preparacion de vectores de expresion.
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
DK1618889T3 (da) Influenzavaccine
NO904538L (no) Kimaere glykoproteiner inneholdende immunogene segmenter av humant parainfluensavirus type 3.
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
ES553758A0 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia.
ES498752A0 (es) Un procedimiento para preparar una vacuna de virus vivos de la peritonitis infecciosa de los felinos
ES2148355T3 (es) Procedimiento para la preparacion de nevirapina.
AR220838A1 (es) Procedimiento para preparar una vacuna de virus de influenza(gripe);procedimiento de propagacion de virus de influenza y cultivo liquido de celulas inoculadas con dicho virus,de aplicacion exclusiva en dicho procedimiento para preparar dicha vacuna
ES2087111T5 (es) Vacuna sintetica para la induccion especifica de linfocitos t citotoxicos.
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
ES500199A0 (es) Un procedimiento para preparar una vacuna de virus de la ra-bia inactivados
ES2059305T3 (es) Proteina del virus de la seudorrabia.
ES432385A1 (es) Un metodo de obtener una cepa de virus de la gripe.
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
AU3115189A (en) Live combination vaccine
ZA941853B (en) Stimulation of immune response by viral protein
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
SE8700466D0 (sv) Vaccines against melanoma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 331102

Country of ref document: ES